Učitavanje...
Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
BACKGROUND: Radium-223 dichloride (Ra-223 Xofigo) has recently been approved as an addition to the host of available therapies in the USA as a treatment option for metastatic castrate-resistant prostate cancer (mCRPC) with bone metastases. This study describes our initial experience in patients trea...
Spremljeno u:
| Izdano u: | Cancer Manag Res |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6135075/ https://ncbi.nlm.nih.gov/pubmed/30233247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S166218 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|